交叉配型可能仍然是临床上进行的最具相关性的组织相容性检测。

The crossmatch may still be the most clinically relevant histocompatibility test performed.

作者信息

Kerman Ronald, Lappin Jacqueline, Kahan Barry, Katz Stephen, McKissick Eva, Hosek Kathleen, Acorda Noriel, Wooley Nicholas, Hoover Angela, Miller Kristah, Rodriguez Luis, Moore Brandt, Melcher Porsha, Biedermann Bridget, Van Buren Charles

机构信息

Department of Surgery, Division of Immunology and Organ Transplantation, University of Texas Medical School, Houston, TX, USA.

出版信息

Clin Transpl. 2007:227-9.

PMID:18642454

Abstract

We evaluated patient sera for flow PRA, FCXM, and end-point donor-antigen titer, and we correlated the results with graft survival. You cannot accurately predict a positive or negative FCXM result-not even when the sera have donor-specific antigens-unless you actually perform a crossmatch. Using fluorescence intensity as a surrogate for antibody concentration does not correlate quantitatively with the occurrence of a positive or negative crossmatch. Therefore, it is imperative to give each recipient a chance at being offered a donor organ by performance of a real-time crossmatch and not rely on a virtual evaluation.

摘要

我们评估了患者血清的流式细胞仪群体反应性抗体（flow PRA）、荧光交叉配型试验（FCXM）和终点供体抗原滴度，并将结果与移植物存活率进行关联。除非实际进行交叉配型，否则无法准确预测FCXM结果是阳性还是阴性——即使血清中有供体特异性抗原也不行。用荧光强度作为抗体浓度的替代指标与交叉配型结果为阳性或阴性的发生情况并无定量关联。因此，必须通过实时交叉配型让每个受者都有机会获得供体器官，而不是依赖虚拟评估。